- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pregabalin Linked to Higher Heart Failure Risk Compared to Gabapentin: JAMA

A new retrospective cohort study published in JAMA Internal Medicine has found that pregabalin, a commonly prescribed nonopioid analgesic, is associated with a significantly higher risk of heart failure events compared to gabapentin. The study analyzed Medicare claims data from a large population of older adults and observed that patients initiated on pregabalin had an elevated incidence of hospitalization due to heart failure. This risk was especially pronounced in individuals with pre-existing cardiovascular conditions. Both pregabalin and gabapentin are used to manage neuropathic pain, but pregabalin has a more potent pharmacologic profile and is often considered the stronger agent. However, this potency may come at the cost of increased cardiac risk. Researchers point out that the mechanism may be related to fluid retention and vasodilation effects, which are more commonly reported with pregabalin use. The findings highlight the need for careful patient selection when initiating pregabalin, particularly among older adults or those with a history of heart failure or compromised cardiac function. Clinicians are encouraged to consider alternative therapies such as gabapentin in patients with elevated cardiovascular risk and to closely monitor for early signs of fluid overload or cardiac symptoms if pregabalin is deemed necessary. While both drugs offer effective pain relief, the study underscores the importance of balancing analgesic efficacy with long-term safety, especially in vulnerable populations. These findings may influence prescribing guidelines and prompt further investigations into the cardiovascular safety profile of commonly used neuropathic pain medications.
Keywords: pregabalin, gabapentin, heart failure, cardiovascular risk, Medicare, neuropathic pain, JAMA, older adults, drug safety, nonopioid analgesic
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.